News & Events
Category: Events 11 May 2022
Gläsernes Labor
„From Target to Market“ - The Pharma Summer School of Gläsernes Labor. Our members Jens Hoffmann, Michael Hildebrand, and Wolf-Stefan Richter will speak during the Summer School event of Gläsernes Labor (31 August – 03 September 2022).
Link: https://www.glaesernes-labor-akademie.de/de/biotech-pharma
Category: Publications 15 April 2022
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Co-authored by Christian Wolf:
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C.
Front Neurol 2022; 13:844873 (full text).
Category: Press Releases 21 January 2022
Angriff auf das zelluläre Netzwerk von Krebs - Neue Option für die Entwicklung wirksamer Therapien bei Lungenkrebs?
Die Behandlung von Patienten mit fortgeschrittenem Lungenkrebs stellt trotz wesentlicher Fortschritte nach wie vor eine große medizinische Herausforderung dar. Die zur Verfügung stehenden Therapieoptionen bedeuten in der Regel zwar eine Verlängerung der Lebenszeit können aber die tödliche Krankheit in den meisten Fällen nur für einen begrenzten Zeitraum aufhalten.
Category: Publications 21 January 2022
Combination is key – new treatments for lung and colon cancer?
Researchers from the Experimental Pharmacology and Oncology (EPO) in Berlin-Buch in cooperation with academic partners identified new experimental approaches to treat therapy resistant cancer.
Category: Events 19 November 2021
Richmond Pharmacology Event – The Future of Healthcare – 8th December
Discover breakthroughs in cardiac health and how they could change treatments for the better. Hear about the latest insights in gene editing, RNA interference therapies, and digital health from the clinical studies experts.
Category: Press Releases 19 November 2021
Dr Ulrike Lorch joins the leadership team at the Faculty of Human Pharmacology
Richmond Pharmacology’s Medical Director, Dr Ulrike Lorch, has been appointed Director of Human Pharmacology for the Faculty of Pharmaceutical Management (FPM).
Category: Press Releases 25 October 2021
Dr Taubel discusses the future of new medicine development and first-in-human studies
In a recent article for PMLiVE and Pharmaceutical Market Europe, Dr Jorg Taubel, CEO of Richmond Pharmacology, outlines the future of new medicine development, influenced by the emergence of gene-based therapies and the reshaping of the way first-in-human clinical studies are delivered.
Category: Press Releases 6 July 2021
Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021. Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.
Category: Publications 19 May 2021
Patient safety is paramount in drug trials
In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
Category: COVID-19 21 April 2021
Richmond Research Institute asks the question, 'Do post-COVID-19 patients need a second dose of vaccine?'
Richmond Research Institute is actively involved in COVID-19 symptoms testing for all staff and visitors who attempt entry to Richmond Pharmacology's London bridge clinical trial unit. The data accumulated throughout this period before and after vaccination has led to the following publication: 'Do post-COVID-19 patients need a second dose of vaccine?